Who Paid My Doc
Eric Kuhlman
Podiatrist, Foot & Ankle Surgery Thornton, CO Doctor of Podiatric Medicine
NPI 1003170333 CMS profile 45306
9005 Grant St, Suite 200, Thornton, CO 80229
General payments
$21,314
Research payments
$65,504
Ownership & investment interest
$0
Research they led as principal investigator
$15,633
Through program year 2025, Eric Kuhlman of Thornton, CO is reported in the CMS Open Payments database as having received $21,314 across 147 general payments and $65,504 in research payments paid to them. Separately, studies naming them as principal investigator received $15,633 in research payments, paid to institutions rather than to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.
General payments for this record sit in the 97th percentile of Podiatrist, Foot & Ankle Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
10 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $2,585 | 18 | |
| 2024 | General | $613 | 14 | |
| 2023 | General | $763 | 21 | |
| 2022 | General | $1,347 | 18 | |
| 2021 | General | $5,180 | 33 | |
| 2021 | Research | $6,000 | 1 | |
| 2020 | General | $10,161 | 29 | |
| 2020 | Research | $40,000 | 5 | |
| 2019 | General | $664 | 14 | |
| 2019 | Research | $19,504 | 8 |
Beside peers
- Eric Kuhlman
- Podiatrist, Foot & Ankle Surgery median
- Middle half of Podiatrist, Foot & Ankle Surgery
- National median
In program year 2025, general payments to Eric Kuhlman were reported at $2,585. Among 6,994 Podiatrist, Foot & Ankle Surgery profiles paid that year, the median was $424 and the middle half received between $139 and $1,306.
Show as a table
| Year | Eric Kuhlman | Podiatrist, Foot & Ankle Surgery median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $664 | $389 | $118–$1,406 | $163 |
| 2020 | $10,161 | $191 | $62–$691 | $114 |
| 2021 | $5,180 | $329 | $104–$1,341 | $132 |
| 2022 | $1,347 | $419 | $125–$1,611 | $149 |
| 2023 | $763 | $377 | $128–$1,164 | $160 |
| 2024 | $613 | $394 | $134–$1,168 | $164 |
| 2025 | $2,585 | $424 | $139–$1,306 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 10 drugsPart D claims
331
Drug cost
$4,078
Branded share of claims
27.5%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Ammonium Lactate | Generic | 40 | $829 | |
| Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen | Brand | 36 | $680 | |
| Ondansetron Odt Ondansetron | Brand | 36 | $457 | |
| Oxycodone Hcl | Generic | 50 | $428 | |
| Terbinafine Hcl | Generic | 30 | $405 | |
| Doxycycline Hyclate | Generic | 21 | $314 | |
| Gabapentin | Generic | 49 | $276 | |
| Clindamycin Hcl | Generic | 21 | $240 | |
| Amoxicillin-Clavulanate Potass Amoxicillin/Potassium Clav | Brand | 19 | $234 | |
| Cephalexin | Generic | 29 | $214 |
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 14,093 Part D prescribers listed as Podiatry; they describe a distribution and say nothing about conduct.
Billing to Medicare
Part B · data year 2024 · 29 billing codesPaid by Medicare
$39,406
Medicare patients
130
Services billed
657
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| High blood pressure | 64% | |
| Arthritis | 63% | |
| Diabetes | 30% | |
| Depression | 26% | |
| Chronic kidney disease | 23% | |
| Ischemic heart disease | 22% | |
| Atrial fibrillation | 15% | |
| COPD | 15% |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Records
161 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Podiatrist, Foot & Ankle Surgery in Colorado
Brett Sachs
Podiatrist, Foot & Ankle Surgery · Wheat Ridge, CO
Jeffrey Lehrman
Podiatrist, Foot & Ankle Surgery · Fort Collins, CO
Keith Jacobson
Podiatrist, Foot & Ankle Surgery · Denver, CO
William Montross
Podiatrist, Foot & Ankle Surgery · Colorado Springs, CO
Dustin Kruse
Podiatrist, Foot & Ankle Surgery · Wheat Ridge, CO
Joshua Thun
Podiatrist, Foot & Ankle Surgery · Grand Junction, CO
Related records
Podiatrist, Foot & Ankle Surgery in Colorado
Practitioners in the same specialty and state, ranked by reported value.
All Podiatrist, Foot & Ankle Surgery
Everyone recorded under this specialty, nationwide.
Doctors in Colorado
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.